Antonelli A, Gambuzza C, Bertoni F, Baschieri L
Institute of Clinical Medicine II, University of Pisa, Italy.
Clin Ther. 1992 Mar-Apr;14(2):178-84.
Three patients with the carcinoid syndrome received intravenous somatostatin (3.5 micrograms/min) for one day; intravenous salmon calcitonin (8 IU/hr) for one day; subcutaneous salmon calcitonin (100 IU three times daily) for ten days; and subcutaneous octreotide (150 micrograms three times daily) for ten days. Octreotide (SMS-201.995) is a stable analogue of somatostatin. There was a five-day washout period between each treatment. During each of these treatments, reductions in the numbers of daily flushes and bowel movements, stool weight, and urinary 5-hydroxyindoleacetic acid (5-HIAA) levels were observed. Relief of cramping abdominal pains was also reported. Patients 1 and 3 chose to continue receiving the subcutaneous calcitonin and patient 2 chose the octreotide. Patient 1 (aged 67 years) reported relief of symptoms for five months until she developed an intestinal obstruction as a result of tumor infiltration. Patient 3 (aged 67 years) has received the calcitonin for about 16 months with relief of symptoms and reduced urinary 5-HIAA levels. Patient 2 (aged 57 years) has continued octreotide treatment for one year and reports relief of symptoms.
静脉注射生长抑素（3.5微克/分钟），持续一天；静脉注射鲑鱼降钙素（8国际单位/小时），持续一天；皮下注射鲑鱼降钙素（100国际单位，每日三次），持续十天；皮下注射奥曲肽（150微克，每日三次），持续十天。奥曲肽（SMS - 201.995）是生长抑素的一种稳定类似物。每次治疗之间有五天的洗脱期。在这些治疗的每一个过程中，均观察到每日潮红次数、排便次数、粪便重量以及尿5 - 羟吲哚乙酸（5 - HIAA）水平有所降低。也有报告称腹部绞痛得到缓解。患者1和患者3选择继续接受皮下注射降钙素，患者2选择了奥曲肽。患者1（67岁）报告症状缓解了五个月，直到因肿瘤浸润出现肠梗阻。患者3（67岁）接受降钙素治疗约16个月，症状缓解，尿5 - HIAA水平降低。患者2（57岁）继续接受奥曲肽治疗一年，报告症状缓解。
